InfraScan

InfraScan operates in medical devices and diagnostics, with a specialized focus on bedside assessment of possible intracranial bleeding after head trauma. Its Infrascanner uses near-infrared (NIR) technology in a portable handheld format, positioning it as a triage aid rather than a substitute for imaging or clinical judgment. The stated use is to help clinicians identify patients who may need CT scans or neurosurgical intervention, which distinguishes the device’s role from the imaging pathway it supports. The Model 1000 received FDA De Novo clearance in 2011, followed by 510(k) clearance for the Model 2000 in 2013. The underlying NIR approach was tested in 305 patients at Baylor College of Medicine, and a 2026 study announcement described its use in traumatic brain injury triage during large-scale combat operations. These details suggest a focused clinical and operational niche, particularly where rapid assessment and portability matter. InfraScan’s small employee band and limited disclosed financing also contrast with larger, broadly diversified medical-device businesses.

InfraScan’s development reflects a long path from academic technology toward cleared clinical products and field evaluation. The company was founded in 2004 around NIR brain-hematoma detection work by Britton Chance and Claudia Robertson, with collaboration from Drexel University. It recorded four seed rounds, dated Mar 16, 2005, Oct 5, 2005, Nov 18, 2008, and Mar 24, 2014. BioAdvance is the sole listed investor. Product clearances mark important inflection points: the Model 1000 received FDA De Novo clearance in 2011, and the Model 2000 received FDA 510(k) clearance in 2013. A 2020 announcement concerned U.S. patents for brain diagnosis, while a study announced on Sep 29, 2026 highlighted the device’s role in traumatic brain injury triage during large-scale combat operations. The company is listed as active and has an employee range of 1–10, but no hiring trend or recent funding beyond 2014 is specified. This profile indicates continued clinical and product activity, although the limited financing and workforce information makes the pace of commercial expansion difficult to judge.